Pentagamavunone-1 inhibits aggressive breast cancer cell proliferation through mitotic catastrophe and ROS-mediated activities: in vitro and in vivo studies

Pentagamavunone-1 (PGV-1), an analog of curcumin, has been studied for its cytotoxic effects in 4T1, MCF7, MCF7/HER2, and T47D breast cancer cells. Its antiproliferative effect is partly mediated through G2/M arrest; however, its molecular mechanism during cell cycle progression remains unknown. In...

Full description

Bibliographic Details
Main Authors: Dhania Novitasari, Ikuko Nakamae, Riris Istighfari Jenie, Noriko Yoneda-Kato, Jun-ya Kato, Edy Meiyanto
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Saudi Pharmaceutical Journal
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1319016423003870
_version_ 1797299747373973504
author Dhania Novitasari
Ikuko Nakamae
Riris Istighfari Jenie
Noriko Yoneda-Kato
Jun-ya Kato
Edy Meiyanto
author_facet Dhania Novitasari
Ikuko Nakamae
Riris Istighfari Jenie
Noriko Yoneda-Kato
Jun-ya Kato
Edy Meiyanto
author_sort Dhania Novitasari
collection DOAJ
description Pentagamavunone-1 (PGV-1), an analog of curcumin, has been studied for its cytotoxic effects in 4T1, MCF7, MCF7/HER2, and T47D breast cancer cells. Its antiproliferative effect is partly mediated through G2/M arrest; however, its molecular mechanism during cell cycle progression remains unknown. In this study, we aimed to determine whether PGV-1 has any anticancer effects on highly aggressive breast cancer cells, with a focus on cell cycle regulatory activity, reactive oxygen species (ROS) generation, and their mediated effects on cancer cells. MDA-MB-231 (triple-negative) and HCC1954 (overexpressed HER2) immortalized human breast cancer cells were used in the study. PGV-1 exhibited cytotoxic activity with an irreversible antiproliferative impact on treated cells and had good selectivity when tested in fibroblast cells. Oral PGV-1 administration suppressed tumor growth in a cell-derived xenograft mouse model. PGV-1 induced the phosphorylation of Aurora A kinase and PLK1 in MDA-MB-231 cells, while PLK1 and cyclin B1 phosphorylation were enhanced in the PGV-1-treated HCC1954 cells during prometaphase arrest. Intracellular ROS production was substantially higher upon PGV-1 treatment following mitotic arrest, and this activity caused impairment of mitochondrial respiration, induced senescence, and subsequently triggered early-to-late apoptosis. Collectively, these results suggest that the molecular mechanism of PGV-1 involves the regulation of mitotic kinases to cause cell cycle arrest and the enhancement of ROS production to impair mitochondrial activity and induce cellular senescence. The therapeutic activities demonstrated by PGV-1 in this study show its potential as an appealing candidate for chemotherapy in breast cancer treatment.
first_indexed 2024-03-07T22:55:08Z
format Article
id doaj.art-3beaaebcb9cd44c68a40035e55421244
institution Directory Open Access Journal
issn 1319-0164
language English
last_indexed 2024-03-07T22:55:08Z
publishDate 2024-01-01
publisher Elsevier
record_format Article
series Saudi Pharmaceutical Journal
spelling doaj.art-3beaaebcb9cd44c68a40035e554212442024-02-23T04:58:39ZengElsevierSaudi Pharmaceutical Journal1319-01642024-01-01321101892Pentagamavunone-1 inhibits aggressive breast cancer cell proliferation through mitotic catastrophe and ROS-mediated activities: in vitro and in vivo studiesDhania Novitasari0Ikuko Nakamae1Riris Istighfari Jenie2Noriko Yoneda-Kato3Jun-ya Kato4Edy Meiyanto5Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta 55281, IndonesiaLaboratory of Tumor Cell Biology, Division of Biological Science, Graduate School of Science and Technology, Nara Institute of Science and Technology, Nara 630-0192, JapanCancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta 55281, IndonesiaLaboratory of Tumor Cell Biology, Division of Biological Science, Graduate School of Science and Technology, Nara Institute of Science and Technology, Nara 630-0192, JapanLaboratory of Tumor Cell Biology, Division of Biological Science, Graduate School of Science and Technology, Nara Institute of Science and Technology, Nara 630-0192, Japan; Corresponding authors at: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia (E. Meiyanto).Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia; Corresponding authors at: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia (E. Meiyanto).Pentagamavunone-1 (PGV-1), an analog of curcumin, has been studied for its cytotoxic effects in 4T1, MCF7, MCF7/HER2, and T47D breast cancer cells. Its antiproliferative effect is partly mediated through G2/M arrest; however, its molecular mechanism during cell cycle progression remains unknown. In this study, we aimed to determine whether PGV-1 has any anticancer effects on highly aggressive breast cancer cells, with a focus on cell cycle regulatory activity, reactive oxygen species (ROS) generation, and their mediated effects on cancer cells. MDA-MB-231 (triple-negative) and HCC1954 (overexpressed HER2) immortalized human breast cancer cells were used in the study. PGV-1 exhibited cytotoxic activity with an irreversible antiproliferative impact on treated cells and had good selectivity when tested in fibroblast cells. Oral PGV-1 administration suppressed tumor growth in a cell-derived xenograft mouse model. PGV-1 induced the phosphorylation of Aurora A kinase and PLK1 in MDA-MB-231 cells, while PLK1 and cyclin B1 phosphorylation were enhanced in the PGV-1-treated HCC1954 cells during prometaphase arrest. Intracellular ROS production was substantially higher upon PGV-1 treatment following mitotic arrest, and this activity caused impairment of mitochondrial respiration, induced senescence, and subsequently triggered early-to-late apoptosis. Collectively, these results suggest that the molecular mechanism of PGV-1 involves the regulation of mitotic kinases to cause cell cycle arrest and the enhancement of ROS production to impair mitochondrial activity and induce cellular senescence. The therapeutic activities demonstrated by PGV-1 in this study show its potential as an appealing candidate for chemotherapy in breast cancer treatment.http://www.sciencedirect.com/science/article/pii/S1319016423003870Curcumin analogMitotic arrestROS generationBreast cancer
spellingShingle Dhania Novitasari
Ikuko Nakamae
Riris Istighfari Jenie
Noriko Yoneda-Kato
Jun-ya Kato
Edy Meiyanto
Pentagamavunone-1 inhibits aggressive breast cancer cell proliferation through mitotic catastrophe and ROS-mediated activities: in vitro and in vivo studies
Saudi Pharmaceutical Journal
Curcumin analog
Mitotic arrest
ROS generation
Breast cancer
title Pentagamavunone-1 inhibits aggressive breast cancer cell proliferation through mitotic catastrophe and ROS-mediated activities: in vitro and in vivo studies
title_full Pentagamavunone-1 inhibits aggressive breast cancer cell proliferation through mitotic catastrophe and ROS-mediated activities: in vitro and in vivo studies
title_fullStr Pentagamavunone-1 inhibits aggressive breast cancer cell proliferation through mitotic catastrophe and ROS-mediated activities: in vitro and in vivo studies
title_full_unstemmed Pentagamavunone-1 inhibits aggressive breast cancer cell proliferation through mitotic catastrophe and ROS-mediated activities: in vitro and in vivo studies
title_short Pentagamavunone-1 inhibits aggressive breast cancer cell proliferation through mitotic catastrophe and ROS-mediated activities: in vitro and in vivo studies
title_sort pentagamavunone 1 inhibits aggressive breast cancer cell proliferation through mitotic catastrophe and ros mediated activities in vitro and in vivo studies
topic Curcumin analog
Mitotic arrest
ROS generation
Breast cancer
url http://www.sciencedirect.com/science/article/pii/S1319016423003870
work_keys_str_mv AT dhanianovitasari pentagamavunone1inhibitsaggressivebreastcancercellproliferationthroughmitoticcatastropheandrosmediatedactivitiesinvitroandinvivostudies
AT ikukonakamae pentagamavunone1inhibitsaggressivebreastcancercellproliferationthroughmitoticcatastropheandrosmediatedactivitiesinvitroandinvivostudies
AT ririsistighfarijenie pentagamavunone1inhibitsaggressivebreastcancercellproliferationthroughmitoticcatastropheandrosmediatedactivitiesinvitroandinvivostudies
AT norikoyonedakato pentagamavunone1inhibitsaggressivebreastcancercellproliferationthroughmitoticcatastropheandrosmediatedactivitiesinvitroandinvivostudies
AT junyakato pentagamavunone1inhibitsaggressivebreastcancercellproliferationthroughmitoticcatastropheandrosmediatedactivitiesinvitroandinvivostudies
AT edymeiyanto pentagamavunone1inhibitsaggressivebreastcancercellproliferationthroughmitoticcatastropheandrosmediatedactivitiesinvitroandinvivostudies